TACSTD2抗体;TACSTD2 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using TACSTD2 mouse mAb against A431 (1), HCT116 (2), PC-3 (3), MCF-7 (4), SK-Br-3 (5), T47D (6), HEK293 (7), and HEK293-6e (8) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of BEL-7402 cells using TACSTD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using TACSTD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using TACSTD2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using TACSTD2 mouse mAb with DAB staining.    

  
  

The TACSTD2 antibody targets the tumor-associated calcium signal transducer 2 (TACSTD2), also known as trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein encoded by the *TACSTD2* gene. TROP2 is broadly expressed in epithelial tissues and plays roles in cell adhesion, proliferation, and signal transduction. It is overexpressed in many solid tumors, including breast, lung, pancreatic, and colorectal cancers, where it correlates with aggressive tumor behavior, metastasis, and poor prognosis. This overexpression makes TROP2 a promising therapeutic and diagnostic target.

TACSTD2 antibodies are primarily used in research and clinical applications to detect TROP2 protein levels via techniques like immunohistochemistry (IHC) or flow cytometry, aiding in cancer diagnosis and biomarker studies. Therapeutically, anti-TROP2 monoclonal antibodies form the basis of antibody-drug conjugates (ADCs), such as sacituzumab govitecan, which delivers cytotoxic payloads directly to cancer cells. These ADCs have gained FDA approval for treating triple-negative breast cancer and urothelial carcinoma, highlighting TACSTD2's clinical relevance. Additionally, TROP2-targeting bispecific antibodies and CAR-T therapies are under investigation. Despite its potential, challenges remain in minimizing off-target effects and understanding TROP2's precise mechanistic roles in oncogenesis. Ongoing research continues to explore TACSTD2's biology and its exploitation for innovative cancer therapies.